The elevated P/S ratio relative to the company's limited revenue generation suggests that investors are assigning a premium to the intellectual property rather than the current sales of APHEXDA. This valuation appears precarious, as the lack of a positive P/E or meaningful EBITDA makes it difficult to justify the current market capitalization without assuming a rapid and unlikely inflection in commercial adoption.

The gross margin of 36.19% is notably low for a specialized pharmaceutical product, which may imply high third-party manufacturing costs or significant royalty obligations that erode the value of each unit sold. Investors should monitor whether these margins can improve through scale or if they remain permanently suppressed by the competitive necessity of discounting in the transplant center market.

The extremely high DIO and DPO metrics indicate that the company is struggling to manage its inventory and supplier relationships effectively during this early commercial phase. This inefficiency in working capital management further exacerbates the cash burn, as capital remains tied up in inventory that is not yet moving through the supply chain at a sufficient velocity.

While the D/E ratio of 0.44 might appear manageable in isolation, the lack of positive EBITDA means that any debt burden is effectively a liability that cannot be serviced by the business model. This reliance on equity markets for survival creates a persistent risk of shareholder dilution, which appears to be the primary mechanism for funding the company's ongoing cash requirements.